Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
100%(8 trials)

Phase Distribution

Ph phase_2
1
13%
Ph phase_4
1
13%
Ph phase_3
6
75%

Phase Distribution

0

Early Stage

1

Mid Stage

7

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
6(75.0%)
Phase 4Post-market surveillance
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (12.5%)
Phase 36 (75.0%)
Phase 41 (12.5%)

Trials by Status

completed8100%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_3

Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder

NCT03569475
completedphase_3

Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

NCT01085812
completedphase_4

A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder

NCT02288325
completedphase_2

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

NCT01254305
completedphase_3

Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder

NCT01377194
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03569475Phase 3

Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder

Completed
NCT01085812Phase 3

Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder

Completed
NCT02288325Phase 4

A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder

Completed
NCT01254305Phase 2

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

Completed
NCT01377194Phase 3

Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder

Completed
NCT00969150Phase 3

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Completed
NCT01034462Phase 3

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Completed
NCT00969709Phase 3

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8